PriceTargets.com logo

Bicycle Therapeutics - BCYC Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $40.13
  • Forecasted Upside: 100.52%
  • Number of Analysts: 9
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 7 Buy Ratings
  • 0 Strong Buy Ratings
$20.01 As of 12/2/2024 01:00 AM ET
▼ -0.39 (-1.91%)

This chart shows the closing price for BCYC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Bicycle Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BCYC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BCYC

Analyst Price Target is $40.13
▲ +100.52% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Bicycle Therapeutics in the last 3 months. The average price target is $40.13, with a high forecast of $60.00 and a low forecast of $25.00. The average price target represents a 100.52% upside from the last price of $20.01.

This chart shows the closing price for BCYC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 9 contributing investment analysts is to moderate buy stock in Bicycle Therapeutics. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 10 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/11/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/9/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/8/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/7/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/5/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
9/3/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
11/2/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
12/2/2024

Latest Recommendations

  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/8/2024StephensInitiated CoverageEqual Weight$25.00
11/1/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$35.00 ➝ $35.00
11/1/2024HC WainwrightReiterated RatingBuy ➝ Buy$55.00 ➝ $55.00
10/31/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$38.00 ➝ $38.00
10/24/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$38.00 ➝ $38.00
10/24/2024HC WainwrightReiterated RatingBuy ➝ Buy$55.00 ➝ $55.00
9/16/2024JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$32.00 ➝ $32.00
9/16/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$38.00 ➝ $38.00
9/16/2024HC WainwrightReiterated RatingBuy ➝ Buy$55.00 ➝ $55.00
9/9/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$38.00 ➝ $38.00
9/9/2024Cantor FitzgeraldReiterated RatingOverweight
9/6/2024Royal Bank of CanadaInitiated CoverageOutperform$35.00
8/7/2024HC WainwrightReiterated RatingBuy ➝ Buy$55.00 ➝ $55.00
8/7/2024OppenheimerReiterated RatingOutperform ➝ Outperform$48.00 ➝ $48.00
8/7/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$38.00 ➝ $38.00
8/7/2024B. RileyDowngradeBuy ➝ Neutral$33.00 ➝ $28.00
5/3/2024HC WainwrightReiterated RatingBuy ➝ Buy$55.00
4/10/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$43.00
2/21/2024Canaccord Genuity GroupReiterated RatingBuy ➝ Buy$60.00
2/21/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$43.00
2/21/2024HC WainwrightLower TargetBuy ➝ Buy$57.00 ➝ $55.00
12/20/2023JMP SecuritiesLower TargetMarket Outperform ➝ Market Outperform$44.00 ➝ $32.00
12/15/2023Needham & Company LLCLower TargetBuy ➝ Buy$46.00 ➝ $43.00
11/8/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$65.00
11/3/2023Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$42.00 ➝ $40.00
9/12/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$46.00
9/12/2023JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$44.00
9/11/2023B. RileyUpgradeNeutral ➝ Buy$33.00
9/7/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$65.00
8/4/2023Morgan StanleyReiterated RatingEqual Weight ➝ Equal Weight$42.00
8/4/2023Needham & Company LLCLower TargetBuy ➝ Buy$48.00 ➝ $46.00
8/4/2023HC WainwrightReiterated RatingBuy ➝ Buy$57.00
8/4/2023JMP SecuritiesLower TargetOutperform ➝ Outperform$46.00 ➝ $44.00
4/19/2023EF Hutton Acquisition Co. IReiterated RatingBuy$55.00
3/1/2023Needham & Company LLCLower TargetBuy$72.00 ➝ $67.00
3/1/2023HC WainwrightReiterated RatingBuy$57.00
2/28/2023EF Hutton Acquisition Co. IReiterated RatingBuy$55.00
2/27/2023Cantor FitzgeraldReiterated RatingOverweight$74.00
2/15/2023Needham & Company LLCReiterated RatingBuy$72.00
2/15/2023HC WainwrightReiterated RatingBuy$57.00
2/15/2023EF Hutton Acquisition Co. IReiterated RatingBuy$55.00
1/5/2023EF Hutton Acquisition Co. IInitiated CoverageBuy$55.00
11/10/2022Piper SandlerBoost Target$37.00 ➝ $48.00
11/9/2022JMP SecuritiesLower TargetMarket Outperform$70.00 ➝ $46.00
9/21/2022Cantor FitzgeraldReiterated RatingOverweight
9/12/2022Morgan StanleyLower TargetEqual Weight$60.00 ➝ $45.00
9/8/2022JMP SecuritiesReiterated RatingBuy$70.00
8/31/2022CowenInitiated CoverageOutperform
8/31/2022CowenInitiated CoverageOutperform
8/22/2022Leerink PartnersBoost TargetOutperform$48.00 ➝ $50.00
8/5/2022Leerink PartnersLower TargetOutperform$69.00 ➝ $48.00
8/5/2022HC WainwrightLower TargetBuy$65.00 ➝ $57.00
7/28/2022BarclaysInitiated CoverageOverweight$30.00
7/6/2022Canaccord Genuity GroupReiterated RatingBuy$60.00
6/6/2022JMP SecuritiesReiterated RatingBuy$70.00
5/23/2022Piper SandlerLower TargetOverweight$76.00 ➝ $37.00
4/13/2022B. RileyDowngradeBuy ➝ Neutral$62.00 ➝ $33.00
4/12/2022Needham & Company LLCLower TargetBuy$85.00 ➝ $75.00
4/7/2022Cantor FitzgeraldInitiated CoverageOverweight$100.00 ➝ $80.00
4/1/2022Cantor FitzgeraldReiterated RatingOverweight$100.00 ➝ $80.00
3/3/2022JMP SecuritiesLower TargetMarket Outperform$85.00 ➝ $70.00
3/2/2022B. RileyLower Target$72.00 ➝ $62.00
2/14/2022Morgan StanleyInitiated CoverageEqual Weight$60.00
12/17/2021Leerink PartnersInitiated CoverageOutperform$70.00
12/9/2021Needham & Company LLCInitiated CoverageBuy$85.00
10/14/2021JMP SecuritiesBoost TargetOutperform$53.00 ➝ $85.00
10/8/2021B. RileyBoost TargetBuy$56.00 ➝ $72.00
10/8/2021Piper SandlerBoost TargetOverweight$46.00 ➝ $76.00
10/8/2021OppenheimerBoost TargetOutperform$47.00 ➝ $65.00
10/8/2021HC WainwrightReiterated RatingPositive ➝ Buy$39.00 ➝ $65.00
10/7/2021Roth CapitalBoost TargetPositive ➝ Buy$35.00 ➝ $65.00
9/30/2021B. RileyInitiated CoverageBuy$56.00
8/11/2021JMP SecuritiesReiterated RatingBuy$53.00
7/13/2021Piper SandlerBoost TargetOverweight$39.00 ➝ $46.00
5/11/2021OppenheimerBoost Target$38.00 ➝ $44.00
5/7/2021HC WainwrightBoost TargetBuy$31.00 ➝ $39.00
5/7/2021Piper SandlerBoost TargetOverweight$35.00 ➝ $39.00
4/20/2021JMP SecuritiesInitiated CoverageOutperform$53.00
1/20/2021Cantor FitzgeraldBoost TargetOverweight$30.00 ➝ $58.00
1/15/2021OppenheimerBoost TargetOutperform$27.00 ➝ $38.00
1/15/2021HC WainwrightBoost TargetBuy$28.00 ➝ $31.00
12/3/2020HC WainwrightReiterated RatingBuy$28.00
10/12/2020Cantor FitzgeraldInitiated CoverageOverweight$30.00
9/22/2020OppenheimerReiterated RatingBuy$27.00
8/6/2020HC WainwrightReiterated RatingBuy$25.00
7/21/2020OppenheimerReiterated RatingBuy$27.00
6/24/2020OppenheimerReiterated RatingBuy$27.00
6/11/2020OppenheimerInitiated CoverageOutperform$27.00
5/8/2020HC WainwrightReiterated RatingBuy$25.00
4/17/2020HC WainwrightInitiated CoverageBuy$25.00
(Data available from 12/3/2019 forward)

News Sentiment Rating

0.87 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 8 very positive mentions
  • 23 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
5/7/2024
  • 7 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/6/2024
  • 6 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/6/2024
  • 8 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/5/2024
  • 7 very positive mentions
  • 16 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
9/4/2024
  • 9 very positive mentions
  • 22 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
10/4/2024
  • 8 very positive mentions
  • 18 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
11/3/2024
  • 9 very positive mentions
  • 14 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/3/2024

Current Sentiment

  • 9 very positive mentions
  • 14 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Bicycle Therapeutics logo
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
Read More

Today's Range

Now: $20.01
Low: $19.92
High: $21.00

50 Day Range

MA: $23.42
Low: $19.95
High: $27.51

52 Week Range

Now: $20.01
Low: $14.33
High: $28.67

Volume

279,083 shs

Average Volume

430,303 shs

Market Capitalization

$951.48 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.86

Frequently Asked Questions

What sell-side analysts currently cover shares of Bicycle Therapeutics?

The following Wall Street analysts have issued reports on Bicycle Therapeutics in the last year: B. Riley, Canaccord Genuity Group Inc., Cantor Fitzgerald, HC Wainwright, JMP Securities, Needham & Company LLC, Oppenheimer Holdings Inc., Royal Bank of Canada, and Stephens.
View the latest analyst ratings for BCYC.

What is the current price target for Bicycle Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Bicycle Therapeutics in the last year. Their average twelve-month price target is $40.13, suggesting a possible upside of 100.5%. Canaccord Genuity Group Inc. has the highest price target set, predicting BCYC will reach $60.00 in the next twelve months. Stephens has the lowest price target set, forecasting a price of $25.00 for Bicycle Therapeutics in the next year.
View the latest price targets for BCYC.

What is the current consensus analyst rating for Bicycle Therapeutics?

Bicycle Therapeutics currently has 2 hold ratings and 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for BCYC.

What other companies compete with Bicycle Therapeutics?

Other companies that are similar to Bicycle Therapeutics include Rhythm Pharmaceuticals, Scholar Rock, MoonLake Immunotherapeutics, ImmunityBio and Agios Pharmaceuticals. Learn More about companies similar to Bicycle Therapeutics.

How do I contact Bicycle Therapeutics' investor relations team?

Bicycle Therapeutics' physical mailing address is B900 BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0, CB22 3AT. The company's listed phone number is 441223261503 and its investor relations email address is [email protected]. The official website for Bicycle Therapeutics is www.bicycletherapeutics.com. Learn More about contacing Bicycle Therapeutics investor relations.